UCSF Catalyst Program

2023-2024 Kunal Patel Catalyst Awards Selection Committee

Ioana Aanei, PhD, is an Associate Director of Business Development and Alliance Management at Scribe Therapeutics, a gene editing spinout company from the Doudna lab at UC Berkeley. Their CRISPR by Design platform encompasses an array of gene modulators based on a proprietary and evergreen CRISPR CasX platform. Ioana was involved in setting up and managing the partnerships between Scribe and Biogen and more recently, Sanofi. Prior to Scribe, Ioana worked as the Entrepreneurship Program Manager at QB3 and the Deputy Director at the UCSF Rosenman Institute, where she helped Bay Area biotech startup companies refine their stories and build their strategies for fundraising and growth. Ioana holds a BS from Caltech and earned her PhD from UC Berkeley in Chemistry.

Isabel Elaine Allen, PhD, is Professor of Biostatistics and Epidemiology and Mentor in Quantitative Biosciences at UCSF and Emeritus Professor of Statistics and Entrepreneurship at Babson College. She founded and led several biotechnology companies, serves on the board and advises several non-profit organizations and analytic & biotechnology start-ups. She is Co-Director of the Babson Survey Research Group and has received multiple research grants to design and conduct surveys on online education and entrepreneurship. She is a Fellow of the American Statistical Association and has received the UCSF CTSI consultant of the year award in the past four years. She has published widely on statistical issues in meta-analysis, analytics, survey research, and clinical research methodology as well as authoring several articles and book chapters on women's entrepreneurship. She consults in the entrepreneurship, pharmaceutical, biotechnology and sports industries and has served on several NIH panels on best practices in statistics and evidence-based research.

Valery Antonenko, MD, PhD, has more than 40 years of experience in the fields of Drug Discovery and Drug Delivery, including novel combinatorial technologies as well as traditional ways of discovering new medicines. He started his career with Professor Murray Goodman at UCSD under the mentorship of key biotech industry founder Alejandro Zaffaroni. Valery led large teams and initiatives at biotech companies such as Affymax Research Institute, Arqule, and Threshold Pharmaceuticals. At Glaxo Smith Kline and Johnson and Johnson, he directed therapeutic programs aimed at improving clinical trial success rate by combining new discovery and delivery technologies with established practices. Throughout his career, Valery has also partnered with teams to raise capital for stem cell-based cancer therapies and consulted on ventures in the biotech field.

Nathan Bachtell, MD, MS, is currently the acting CMO of IHP Therapeutics, an early stage biotherapeutics company focused on disease modifying therapies in Sickle Cell Disease and Oncology. He is also a consultant to early stage gene therapy companies and mentor to physicians coming into the life science industry. Prior to this Nate served as senior vice president at Astellas Gene Therapy (AGT), where he led all development functions across a multi-platform GT franchise targeting rare neuromuscular diseases. Prior to AGT, he was the CMO of Symic Bio, from its inception in 2014 through 2019, taking a benchtop platform technology through late-stage clinical development in multiple therapeutic areas. Nate's early experience was at Genzyme (now part of Sanofi) where he worked on drugs, biologics, first generation cell therapies and medical devices where he led teams in pharmacovigilance, clinical research and medical affairs. His therapeutic area development experience includes rheumatology, immune mediated diseases, orthopedics, dermatology, neurology, cardiovascular and neuromuscular diseases. Prior to industry, Nate practiced internal medicine as an inpatient attending physician and served as a principal investigator and advisor to early-stage life science companies. He received his MD from UC San Francisco, completed residency at Oregon Health Sciences University and earned a masters in management from Harvard University's Extension Program.

Shreya Badhrinarayanan, MD, is the Medical Director for Clinical Development Oncology at Genentech, a subsidiary of Roche. In this role, she provides strategic direction for the development of new Immuno-Oncology drugs by leading cross-functional teams and conducting medical monitoring of clinical trials. Prior to her current position, she served as a Physician with the National Health Service (NHS) in the UK, where she made significant contributions to clinical and research initiatives. During her time there, she also played an active role in the RECOVERY Trial, the world's largest clinical trial for COVID-19 treatments. Thriving in the field of medical leadership and management, Dr. Badhrinarayanan received the Edward Jenner Award from the NHS Leadership Academy. She has helped shape early-stage digital health and biotechnology startups in her capacity as a scientific advisor at the UCSF Health Hub. Her wide range of interests varies from AI in health care to D&I initiatives that have been embodied through her contributions to print and media as well as at conferences across the globe

Chris Baker, MD, has been at Children's Hospital Oakland (now UCSF Benioff Children's Hospital) as an attending in the department of Emergency Medicine. He has a research interest in concussion and bronchiolitis. He founded his own company in the ENT space, developing a portable nasal wash and specimen collection system for babies. It received funding from the BARDA division of US Health and Human Services. Finally, he has also worked with Aphelion Capital, a medical technology venture firm in evaluating new medical technology.

Pam Baker, MBA, is a life sciences professional with 17 years of experience in pharma, biotech and diagnostics in a series of commercial roles across marketing, new product commercialization, reimbursement, pipeline and sales management. She started her healthcare career 17 years ago, beginning with Johnson & Johnson (Janssen, Ortho and Mc Neil), followed by Genentech. Ms Baker started out in sales, then moved into sales training, sales leadership and to multiple marketing roles, from product launch, to in-line marketing. She then moved into the reimbursement arena, leading the Program Strategy & Management team for Genentech Access Solutions. Pam received a Bachelor of Arts, Political Science and Asian Studies from Northwestern University and a Master, International Management from Thunderbird School of Global Management. She is a mom of twin girls.

Priya Balachandran, PhD, is a leader in the life science technology space with a passion for improving human health. She has deep experience in commercializing disruptive innovations impacting outcomes in health and wellness. Her expertise in Product and Go-To-Market strategies has a global span, across portfolios of varying sizes in genomics, diagnostics, healthcare, sports medicine, and consumer markets (including regulated products). Her product portfolios include consumables, hardware, and software. Dr. Balachandran is a successful researcher with peer-reviewed publications and patents.

Rick Beberman, MBA, MAcc, is an investment and corporate development professional with an extensive background in health information technology and digital health. He is currently a member of the advisory board of Trinity Health, an early stage company that has developed a virtual meeting room to assist multidisciplinary medical teams deliver more effective team-based care. Rick was a venture associate with Health Care Investment Visions, an organization that invests in seed stage health information technology companies and led business development for one of its portfolio companies. Rick was a founder of a digital health company that developed software to help primary care doctors make more effective patient diagnoses. For fifteen years, Rick was an investment banker with the North American affiliate of NM Rothschild & Sons and later with Banc of America Securities. Rick has an MBA from New York University and a Master's degree in accounting from the University of Southern California.

Ellen Berg, PhD, is a senior scientific leader in translational human biology for drug discovery, consumer product and chemical safety applications. Experience in the development and commercialization of new technologies for translational research including business unit responsibility. Broad understanding of drug efficacy and chemical toxicity mechanisms. Skilled in the analysis of complex phenotypic assay data sets connecting in vitro data to in vivo outcomes. Lead inventor of BioSeek's BioMAP human primary cell-based

profiling platform, now a service of DiscoverX Corporation. Areas of interest include phenotypic drug discovery, alternative methods to animal testing, and computational methods for predictive biology using chemical biology tools.

Beth Berrean, MBA, is Deputy Director for Design and Discovery with UCSF's Information Services Unit (ISU). Beth works with faculty and leadership throughout the enterprise to help shape their ideas into digital products and services. She is leveraging ISU's full solution architecture team and UCSF's enterprise technology groups. Beth helps internal innovators identify executable product roadmaps. Beth has a background in user-centered design, an MBA from CCA's Design Strategy program and 15 years of experience working across various technologies.

Mike Billig co-founded Experien Group in 2003 with his wife and business partner Darlene Crockett-Billig as a full-service consulting firm for the medical device industry. As CEO, Mike provides strategic regulatory guidance to the firm's clientele, frequently representing companies in FDA interface, notified body negotiations, board of directors' meetings, due diligence activities and more. Mike's entire professional career has been involved with regulatory affairs, quality systems, clinical research and general management for medical device companies. He entered the industry in 1973 at Medtronic and went on to work for a number of other successful companies, including Guidant, Oximetrix, Abbott and Syntex. Mike held executive-level positions for over 20 years at early stage start-up companies, including Converge Medical, Systems, CardioThoracic Systems, Cardiometrics, and Timi3 Systems where he was President and CEO. Mike has secured U.S. and international regulatory approval for hundreds of medical devices. He has been involved with a variety of product areas, including sterile disposables, electronic instruments, capital equipment and wireless health. Mike has been instrumental with multiple successful IPOs, as well as substantial fundraising and corporate acquisitions.

Robert Blazej, PhD, directed Novozymes' Digital Biotechnology unit in San Francisco and their global biotechnology scouting team for the past four years. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that mircrodoplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013. Robert earned his Ph.D. in 2006 in Bioengineering jointly from UC Berkeley and UC San Francisco. His graduate research focused on the design, implementation and characterization of microfluidic systems for next-generation DNA sequencing. Blazej is a published contributor to the human, drosophila, and canine genome projects, with his work on integrated microfluidic DNA sequencing featured on the cover of PNAS and in Nature.

Sarah Bodary-Winter, PhD, is the Founder and Principal of Darwin Bodary Consulting. Previously Dr. Bodary served as New Ventures Lead at Johnson and Johnson Innovation, California. She is experienced in drug and business development as well as company creation and venture investing. Previously, Sarah was a Venture Partner as SV Life Sciences where as a member of the therapeutic investing team, she was involved in evaluating investment opportunities, starting Arsanis Biosciences and served on the board of Itero Biopharmaceuticals. Prior to venture capital Sarah was a member of the management team at Schering Plough Biopharma as a Director of Business Development, where she helped transform DNAX Research Institute into the early stage biologics engine for Schering Plough and managed the biologics business development efforts. As a scientist at Genentech, Sarah led numerous therapeutic product teams targeting Integrins, from target identification and validation through Phase 1, and was a member of the Raptiva antibody late stage development, BLA filing and launch teams. She is an author on numerous peer reviewed journals and an inventor on over 30 patents., Sarah earned her B.Sc. in Molecular Biology at the University of Edinburgh, Scotland and a PhD in Molecular Biology at the University of Lausanne/ISREC, Switzerland. She was a postdoctoral scholar at UCSF in Molecular Neurobiology.

Dan Burnett, MD, MBA, received his degrees from Duke University and completed his residency at the Mayo Clinic. He has worked briefly at the FDA and was a General Partner at a medical device focused venture capital firm from 2003-05. Dr. Burnett holds a medical license in California and he is an Associate Professor in the Department of Bioengineering at UCSF where he also acts as Industry Director for the Masters of Translational Medicine program. Since 2006 he has founded nine TheraNova spinouts which have collectively raised over $250M in capital.
In addition to his commercial efforts Dr. Burnett has been very active in the nonprofit community. He has volunteered at the Haight Ashbury Free Clinic, participated in medical missions to Central America and formed two nonprofits, one to design medical devices for low to middle income countries (LMIC) and one to send unused supplies to LMICs.

A. Ray Chaudhuri, PhD, MBA, is a serial entrepreneur, angel investor and operator with ~15 years of experience. He currently advises five startups in the US and Asia including two digital health companies based in US, Europe and India and is also a healthcare expert for two venture funds. Most recently Ray was at Zymergen where he was leading business development of the Healthcare AI company in Europe and Asia. Previously, he was hired to be the CEO of Bontriage, a neurology focused digital health company in Silicon Valley which he grew it from a concept stage to having full scale operations. In the past, he also assisted in the growth of a precision medicine company to a $500M valuation in 18 months - from 12 employees to 700 and $3M ARR to $150M and also assisted in the raise of $55M.

Julie M. Cherrington, PhD, is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®. Dr. Cherrington most recently served as President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs. Previously, she has served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company.

Anand Chokkalingam, PhD, is Senior Director of Clinical Research at Gilead Sciences, where he leads or has led drug development initiatives for COVID-19, viral hepatitis, and other liver disease. He previously headed the Epidemiology unit for Gilead's liver disease portfolio, leading post-authorization/post-marketing studies around the globe and applying pharmaco-epidemiology methods to real world data. Anand is also an Associate Adjunct Professor of Epidemiology at the UC Berkeley School of Public Health. He came to Gilead in 2013 after eight years on faculty at UC Berkeley, where his research focused on molecular and genetic epidemiology of childhood cancers and prostate cancer. He has worked previously for several biotech and molecular diagnostics companies including Syva/Syntex, Celera, and Tethys. He has a B.A. in Biochemistry from UC Berkeley and both an M.S. in Preventive Medicine and a Ph.D. in Epidemiology from the University of Maryland Baltimore, and he completed a post-doctoral fellowship in Cancer Epidemiology at the U.S. NCI's Division of Cancer Epidemiology and Genetics.

Suzanne K. Coberly, MD, MS, is a board certified human anatomic & molecular pathologist with over 20 years of experience in the biotech, IVD, and companion diagnostics industry. Along with her husband and business partner, she is currently the Principal Pathologist & Co-founder of Chimeric Enterprises Pathology Consulting. Previously, she was Senior Director for Translational Pathology & Tissue Analytics in the Translational Oncology group at AbbVie, where she directed translational pathology research for antibody and immuno-oncology therapeutics, developed CDX prototype assays, and evaluated new pathology technologies (digital AI pathology, multiplex, and molecular spatial assays) for use in biomarker and potential clinical assays.

Zach Collins, PhD is an Associate at Mission BioCapital and Head of Academic Alliances at MBC Biolabs – an incubator and venture fund that trace their founding back to UCSF. At Mission BioCapital, Zach provides technical coverage for nine of their active portfolio companies and supports diligence on new investment prospects in the Bay Area. Previously, Zach was a Post-Doctoral Fellow at Harvard Medical School. His scientific research focused on applying cutting edge tools in genetics, genomics, and imaging to the study of stem cell differentiation in the early embryo. This work resulted in several peer-reviewed publications and was recognized by the journal *Science* as 2018's Breakthrough of the Year. Zach holds a PhD in Biological and Biomedical Sciences from Harvard University and a Bachelor of Science in Biology from The George Washington University.

Douglas Crawford, PhD, is a General Partner at BioInnovation Capital. He is Managing Director of Mission Bay Capital and runs QB3@953, the San Francisco shared laboratory. Formerly, Doug was Associate Director at QB3, an activity in the UC system. In the last ten years, Doug has built an entrepreneurial ecosystem that helps launch more than 75 companies per year and created an incubator network with five sites and 86 companies. In addition, Doug has founded two seed stage venture funds, Mission Bay Capital Fund I and Fund II. Companies in the combined portfolio have raised more than $500 million and created greater than 500 jobs. Doug is the primary partner, overseeing all investments, managing fund operations, and overseeing the funds' support of their portfolio companies. To date, he has been responsible for over twenty investments, of which three have been exited (Redwood BioSciences, iPierian, and Calithera). He is a Board member or observer at Delpor, Magnamosis, Magnap, Ocular Dynamics, Avexegen, and Zephyrus.

Maureen Cronin, PhD, acts as CSO at HTG Molecular Diagnostics and is an independent biotechnology consultant. She took retirement from Celgene Corporation as Executive Director of Strategic Information Management in 2017. In this role, she worked cross-functionally within Research and Early Development, with outside collaborators and Celgene IT business partners to create the scientific computing and data management environment necessary for conducting drug development as a knowledge-driven enterprise across multiple, global R&D sites. Prior to joining Celgene, Maureen served as SVP of Research and Product Development at Foundation Medicine in Cambridge, MA where she led development and validation of FoundationOne™, an NGS technology-based oncology clinical diagnostic test. Before joining Foundation Medicine, Maureen was Vice President of Translational Research at Genomic Health, where over her nine-year tenure she built R&D analytical and laboratory capabilities for developing, validating, and launch of the OncotypeDX™ breast and colon cancer tests.

Roxanne Croze, PhD, is a Cell Biologist with a background in Cell and Gene Therapy for a variety of disease indications including, lung, retina and cardiac. She completed a Ph.D. from UCSB in Cell and Molecular Biology with a focus on retinal stem cell biology followed by a post-doctoral fellowship at UCSF examining mesenchymal stromal cells and lipid mediators as a therapy for lung disease. She is a Bay Area native with 5+ years industry experience at a leading gene therapy company, 4D Molecular Therapeutics. Currently she is the Director of Vector and Product Development and runs a team of scientists to support the discovery of novel tropic AAV capsids and progress product candidates through the pipeline towards IND filing in a wide range of therapeutic areas. She is passionate about discovering therapies in areas with unmet medical need to help the millions of suffering patients.

Nipun Davar, PhD, MBA, is the Senior Vice President of Pharmaceutical Development and Manufacturing at Astex Pharmaceuticals, Inc. He had joined Astex in February 2016. He has 22 years of experience in product development in the pharmaceutical industry, particularly process chemistry, formulation development, drug delivery, CMC regulatory, quality assurance, analytical sciences, and manufacturing. He joined Astex from Threshold Pharmaceuticals where he was a Corporate Officer, Senior Vice President and a member of the executive management team from 2011 to 2016, and led the pharmaceutical development of the company's lead oncology product, TH-302. From 2006 to 2011, he was Vice President of pharmaceutical sciences with Transcept Pharmaceuticals where he led the technical product development of Intermezzo® (low dose sublingual zolpidem tartrate), approved by the FDA for the

treatment of middle-of-the-night insomnia. He has authored 13 issued or pending patents and multiple publications in the area of drug delivery and product development. Dr. Davar holds a Ph.D. in Pharmaceutical Sciences from the University of Maryland and an MBA from the Wharton School at the University of Pennsylvania.

Derick En'Wezoh, MD, MBA, is an entrepreneurial physician and investor at Susa Ventures where he specializes in AI/ML-powered technologies and the cutting edges of healthcare. Prior to becoming an investor, Derick started a medical device company in the drug delivery space and was an early team member at Viz.ai where he led growth for nearly four years. Derick was a surgical resident at Stanford Hospital. He completed his MD at Harvard, his MBA at Stanford, and is an alumnus of Stanford Biodesign.

Kenneth Fang, MD, has extensive corporate experience and a proven track record in biomarker discovery and applications for the development and commercialization of diagnostic products for diverse indications, including cardiovascular disease and inflammation. Dr. Fang served as CMO at Diadexus from 2014 to 2016. Prior to joining Diadexus, Dr. Fang served as CMO and VP, Translational Research and Clinical Development, for Integrated Diagnostics, Inc., a molecular diagnostics company, and was head of translational medicine and clinical development for Modus BioMedicine, a start-up company developing monoclonal antibodies targeting lymphocytes as therapeutics for immune-mediated diseases. In 2004-2009, Dr. Fang was senior director, clinical development at XDx, Inc., a molecular diagnostics company. Dr. Fang received a B.A. in biochemistry from the University of Pennsylvania and his M.D. from the University of Pennsylvania School of Medicine. He is Board-Certified in Pulmonary Diseases and Critical Care Medicine. In addition, Dr. Fang was an assistant professor of medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco.

Tony Fields, MS, MSc, served as the Chief Operating Officer of Claret Medical, having joined as the 7th employee in August 2011. Tony managed all aspects of the development of the Sentinel Cerebral Protection System, a catheter designed to protect the brain from stroke during structural heart procedures. Claret was acquired by Boston Scientific in August of 2018. Prior to Claret, he served for two years as the Vice President of Research & Development and Operations for Voyage Medical, managing the development of an image-guided cardiac ablation catheter and system to treat complex arrhythmias. For over eight years prior to Voyage Medical, Tony was the first employee and Vice President of Research and Development for Emphasys Medical, a startup focused on developing a one-way valve mounted on a self-expanding stent for implantation in the airways of the lung to treat emphysema. Prior to Emphasys, he spent over two years as the Vice President of Engineering at Reconstructive Technologies, a startup attempting to grow human skin in vitro, and eight years at IDEO Product Development managing numerous consulting projects in medical devices from infusion pumps to clinical lab instrumentation to drug delivery systems. He is currently working with and advising several early stage medical device companies in addition to working as a patent expert witness. Tony holds a B.S. in Mechanical Engineering from U.C. Berkeley, a M.S. in Mechanical Engineering from M.I.T., and a M.Sc. in Electrical Engineering from Imperial College in London. Tony is an inventor on 26 granted US patents, and numerous other granted OUS patents and pending US/OUS applications.



Bret Foreman, MSEE, is formally trained as an electrical engineer with a BSEE from the University of Southern California and a Masters from UC Berkeley. His engineering specialties are sensors, embedded processors, realtime, nano-power, analog electronics, signal processing, and radio communication. His medical device specialties are in neurostimulators, implanted electronics, surgical robots, and system design in regulated industries. He now works part time as an independent consultant. He enjoys time hiking with his dog, organizing dinner parties, and tricking out his "overland" Tesla Model Y.

Stephen B. Freedman, PhD, is Director of the Gladstone Center for Translational Research (GCTR) and Vice President for Corporate Liaison and Ventures at the Gladstone Institutes. Through Dr. Freedman's leadership, GCTR has facilitated a number of significant strategic relationships and alliances—across all of Gladstone's research areas—with biotech and pharmaceutical companies, venture capital firms and foundations. GCTR is always looking for new opportunities to advance Gladstone's research through both traditional and non-traditional collaboration models. Dr. Freedman has more than 25 years of experience in the pharmaceutical industry, including senior positions at Merck & Co. and Elan Pharmaceuticals. Dr. Freedman earned a bachelor's degree in physiology and biochemistry and a PhD in pharmacology from the University of Southampton. He received the G. Kerkut Prize for Physiology in 1978 and completed postdoctoral studies with Professor Richard Miller at the University of Chicago.



Jonathan Freudman, MD, has over thirty years of experience in healthcare. He founded Freudman Healthcare Consulting in 2002 to bring his clinical, administrative, and business experience to healthcare firms. Jon helps his clients understand and navigate the US healthcare reimbursement system. Clients include medical device manufacturers, disease management companies, telehealth entrepreneurs, and investment firms. Core competencies include identification of drivers for new technology adoption as well as planning and implementation of effective reimbursement strategies.



Ron Garren, MD, is a board-certified internist, and has been practicing medicine for over 40 years. He is a graduate of Harvard Medical School and completed his residency at New York Hospital. In 1994 Ron completed a three-year postdoctoral fellowship in molecular biology at Stanford in Dr. Paul Berg's lab, studying the effects of the nef gene from the HIV virus. An additional year was spent as a visiting scholar in the Biochemistry Dept. at Stanford. Dr. Garren has continued to practice hospital-based oncology as well as consult for biotechnology companies in the San Francisco Bay area. He has a founder equity position in Rigel Pharmaceuticals (RIGL), a public biotech company in South San Francisco. He was also the Chairman of the Board of Kinexis, a private biotech company in San Diego specializing in Alzheimer's disease. Garren was also the CEO of Amplimed, a private biotech company in Tuscon specializing in developing cancer drugs. He was the editor of Biotech Insight, a small-cap biotech newsletter for 20 years. Dr. Garren currently consults for a group of small-cap biotech investors.

Michi Garrison, MS, is a seasoned, hands-on medical device executive, specializing in developing ground-breaking new devices and clinical procedures. She has over twenty-five years of experience in areas ranging from catheters, disposable devices, vascular implants, surgical instruments and medical instrumentation as well as a history of creativity and innovation, with a strong knowledge of intellectual property development.

Marlene Grenon, MD, MBA, is the Chief Medical Officer of Evry Health, a start-up health care insurance as well as a staff physician and Volunteer Associate Clinical Professor in the Department of Surgery at UCSF. She has more than 20 years of experience in the health care industry. Prior to joining the team at Evry Health, Dr. Grenon held a position of Associate Professor in the Department of Surgery at UCSF, staff surgeon at the VAMC San Francisco and Adjunct Faculty at the International Space University. She was heavily involved in research and education, acting as lead investigator for several clinical trials funded by the NIH, NASA/NSBRI, and other organizations. Dr. Grenon holds an M.D. from McGill University, a M.M.Sc. from Harvard Medical School, an M.B.A. from Brown University / IE Business School, and a diploma in Space Sciences from the International Space University.

Elizabeth Gress, MPA, is a graduate of Williams College and has held various research development and program management roles in the Department of Surgery since 2007. In 2017, she earned a Master of Public Affairs degree from UC Berkeley. As Program Manager, Liz plays a key role in goal-setting, strategic planning, and execution of Surgical Innovations' programs and activities. Liz has been involved in Surgical Innovations since its inception, helping develop and launch the initiative in 2012 and now managing its operations. Working closely with faculty leadership, Liz oversees Surgical Innovation's accelerator and seed funding program, organizes project teams, performs program outreach, and coordinates with stakeholders across campus to develop policies and resources to improve the climate for surgical innovators at UCSF. Liz came to her present position after several years as the administrator of the UCSF Pediatric Device Consortium, an FDA-funded "think tank" for pediatric medical device development that has incubated over 15 new pediatric devices and led to six spin-out companies. A successful grant writer, Liz has helped raise over $9 million in government and private funding for medical research, device development, and innovation infrastructure at UCSF. She is also experienced with FDA regulatory submissions, UCSF laboratory and clinical research protocols, and technical writing and editing.

J. Russel Grove, PhD, has worked for 30 years in the biopharmaceutical industry, at companies including Affymax, Abgenix, Amgen, and Boehringer Ingelheim, prior to his joining Coherus BioSciences, where he is Vice President, Regulatory Affairs CMC. His experience includes discovering and developing small-molecule drugs and biologics; leading bioinformatics; evaluating and developing new technologies; developing, transferring, and overseeing biologics manufacturing processes; leading global development teams; and driving regulatory submissions. He earned his AB in Biochemistry from UC Berkeley and his PhD in Pharmacology from Stanford University.

Martyn Gunning has more than 30 years of international pharmaceutical industry experience. A successful background in research, development, project and alliance management of ethical pharmaceuticals. Martyn combines a background in working with major pharmaceutical companies, alongside co-founding several start up biotech companies. Martyn is a biologist and currently runs his own consultancy company assisting pharmaceutical and biotech companies on product development.

Shalabh Gupta, MD, founder, CEO, and President of Unicycle Therapeutics, Inc. since August 2016. Since June 2013, Dr. Gupta has also served as the founder and Chief Executive Officer of Globavir Biosciences, Inc., a company focused on commercializing novel therapeutics and powerful diagnostics for treating global infectious disease. Dr. Gupta has also served in various other capacities including founder and Chief Executive Officer of Biocycive Inc.; Strategy, Genentech Commercial at Genentech, Inc.; Equity Research, Pharmaceuticals at UBS Investment Bank; Attending Physician at NYU Medical Center; clinical faculty member at NYU School of Medicine; and Equity Research, Biotechnology at Rodman & Renshaw, LLC. In addition, he has served on the board of directors of Beall Center for Innovation and Entrepreneurship since 2018. Dr. Gupta has also served as an advisor to SPARK, Stanford University School of Medicine since 2012, a charter member of TiE, a not-for-profit network of entrepreneurs fostering entrepreneurship, mentoring and education, since 2013.

Ken Haas, JD, is a business and biotechnology consultant. He spent 15 years as a Partner at Abingworth, a global life sciences venture capital firm, prior to which he spent 25 years in the management of both early-stage and public technology and biotechnology companies. He was Co-Chair of the Advisory Council to the Neuroscience Institute at Stanford, was part of the founding management team at IntelliGenetics, one of the world's first bioinformatics companies, and served for 10 years as CEO of IntelliCorp, a publicly-traded enterprise software company. At the beginning of his career, he practiced as an attorney in the business and technology group of Heller, Ehrman, White & McAuliffe. Ken's directorships include or have included Aculys, eFFECTOR, Gynesonics, Intellikine, SFJ Pharmaceuticals, Sonitus Medical and Zogenix. He received his BA from Harvard College, an MA from the University of Sussex, a JD from Harvard Law School and attended the Advanced Management Program at Harvard Business School.

Kevin Hacker, PhD, is serving as R&D Scientist, Advanced, in the Emerging Technologies Group in Genomics R&D at Agilent Technologies. He is assisting in IP and FTO inquiries and supporting lab based POC and evaluation efforts. He has worked for Complete Genomics, Cepheid, Molecular Probes, Protein Simple, and Applied Biosystems and was co-founder and CEO of a diagnostic startup. He has aided in the development of 4 instrument platforms and launched 5 products. He received his Ph.D. from UCSF with Bruce Alberts as his advisor.

Karl Handelsman, MBA, MS, in collaboration with scientific founders and entrepreneurs Karl fosters early stage life science innovation. He focuses on early stage pre-clinical therapeutic companies and synthetic biology. The startup search by entrepreneurs and the biotech industry to translate science into products is an evolving practice. In addition to working with science research organizations, such as UCSF and NIH, on translational programs he also makes angel investments in seed and series A startups.

Rami Hannoush, PhD, serves as General Partner at Mubadala Capital. He is an early stage biotech and life science investor with operational experience in pharma R&D. Additionally, Rami has served in various leadership roles in drug discovery and development at Genentech, overseeing the pre-clinical scientific strategy from early stage discovery to development for multiple drug candidates. His focus disease areas are in immunology, ophthalmology and oncology.

Dave Harrison, MD, MBA, is a practicing Emergency Medicine physician and MedTech entrepreneur. He has experience commercializing academic technologies and is the Co-founder and Chief Operating Officer of Theseus AI. In the past, Dave has supported university startups and helped incubate academic projects while working at the UCLA Technology Development Group. Dave was also responsible for MedTech investments at the UCLA Innovation Fund. He has a clinical background as a board certified Emergency Medicine physician with a part time appointment at the Zuckerberg San Francisco General Hospital. He received his B.A. in Economics and MD/MBA from Tufts University and completed his residency at L.A County / University of Southern California.

Chris Haskel, PhD, is the Vice President and Head at the Bayer West Coast Innovation Center with a focus on developing partnered research programs between Bayer's global research activities and early programs in academia and biotech. His focus is on developing innovative business and collaboration models that drive the project to clear decision points based on solid science.

Dan Hayes, PhD, is graduate of the Penn State Engineering Science and Mechanics Doctoral program and is the current Department Head and a Professor in Biomedical Engineering at Penn State University. Dan also serves the as the Director of the Center of Excellence in Industrial Biotechnology at Penn State. His research activities are focused at the intersection of engineered materials and biological systems, with applications in healthcare diagnostics, tissue engineering and drug delivery. His current research is supported by grants from NIH, NSF and DOD. Dan is active in translational research and tech transfer and is the co-founder of several university spin-outs including Illuminate Therapeutics Inc, Osteosynth LLC. and NanoHorizons Inc. Dan has authored over 100 peer-reviewed publications and is an inventor on more than 20 pending and allowed patents.

Andrew Hertz, MD, is an Innovative and visionary physician executive who inspires both physicians and organization leaders to transform operations, increase market share, and optimize the quality and value of care delivered. He is skilled in utilizing clinical and financial data to provide actionable insights to drive change and promote a culture of data driven decision making. Dr. Hertz has a proven track record of engaging physicians and advanced practice providers and leading through rapid changes in the healthcare environment utilizing supportive IT solutions. He has repeated success at developing leadership teams that

embrace transformation, implement novel care delivery models and achieve results. Dr. Hertz is a pioneer, change agent and physician leader who achieves operational success while striving to optimize the well-being of children.

James Hong, MS, is currently President of Solinas Medical and an active advisor to early-stage companies. His career spans R&D engineering to founding Solinas through its acquisition. James started his career at UCSF developing computational models for heart mechanics before joining Guidant (now Abbott) in 2000 as an R&D engineer. Subsequently, he served in engineering management or consulting positions with various early-stage medical device companies focused on product development and fund-raising strategy. He has successfully spearheaded efforts in gaining regulatory issuance and raising venture capital through preferred stock sales, distribution agreements, and NIH and NSF SBIR research grants. James has degrees in mechanical engineering with a B.S. from Purdue University and M.S. from MIT. He is an inventor on 16 issued U.S. patents and co-author on 6 peer-reviewed publications.

Ed Hurwitz, JD, MBA, serves as Managing Director at MPM Capital. Previously, Ed served as Managing Director at Precision BioVentures LLC where he focused on founding and seeding start-up biotechnology companies, including Viewpoint Therapeutics. Prior to that, Ed was a Director of two funds at Alta Partners — Alta BioPharma Management III and Alta Partners Management VIII. While at Alta, Hurwitz led twelve successful investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), MacroGenics, Inc., and Taligen Therapeutics (acquired by Alexion). Over the course of his career, Hurwitz has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotech research analyst for both Robertson Stephens & Company and Smith Barney Shearson. Prior to that he practiced law at Cooley Godward LLP. Hurwitz earned his JD and MBA degrees from the University of California, Berkeley's Boalt School of Law and Haas School of Business, and his BA in Molecular Biology from Cornell University.

Herbert Hurwitz, MD, is a Hematology Specialist in Durham, NC at Duke University with over 32 years of experience in the medical field – mostly focused on Pancreatic Oncology. Clinical Interests and skills include: phase I clinical trials involving new anti-cancer drugs; drug combinations; and combinations of new drugs with radiation; cancers of the GI system.

Stuart Hwang, PhD, is a biotech corporate development advisor with over 15 years in pharmaceutical business development and over 20 years in drug and diagnostic development with a cumulative transaction value greater than $2B, mainly in early stage programs. Working closely with management and the board, he has supported emerging and established biotech companies and investors develop and execute on corporate strategy and transactions including partnerships, licensing, fundraising and M&A. Currently, he is the President of Digestome Therapeutics. He was the Chief Business Officer of Quadriga Bioscience, a seed stage oncology therapeutics company and a Managing Director at Mavericks Capital a biotech focused investment bank. He led business development at Astex (acquired by Otuska).
Stuart is an inventor on several patents, authored 20 journal articles and presented at numerous global scientific and business conferences.

Laurence J. (Larry) Hyman, J.D., M.S., is Of Counsel to the intellectual property boutique of canady + lortz LLP. Mr. Hyman was a partner at Townsend and Townsend and Crew LLP, a national, IP-focused firm (now merged into Kilpatrick Townsend & Stockton LLP). Prior to joining Townsend, Mr. Hyman was with the National Institutes of Health's Office of Technology Transfer, where he served as the lead patent advisor for general medicine. He focuses his practice on biotechnology patenting, strategic planning and counseling, technology licensing, intellectual property due diligence, patent portfolio evaluations, and portfolio management. His clients have included the U.S. Government, universities and research institutes,

start-up and medium sized biotechnology companies, venture capital groups, and pharmaceutical companies. He is a member of the bars of California and New York and is a registered patent attorney. Mr. Hyman earned his law degree from the Boston University School of Law, his M.S. in Biology from Georgetown University, and his B.A. in Biological Sciences from the University of Chicago.

Sharat Israni, PhD, is an original "Big Data" leader and software executive at pioneering companies, who prefers to go where Data Science (and computation) have yet to arrive.... but will. He has spent the last several years with Data Science for Medicine and Public Health. Dr. Israni leads with vision, technical and product foresight, and follow a strategy - keeping close to a North Star has led to notable innovative and transformational achievements. He is a trusted advisor, with a penchant for mentorship.

Wesley Jackson, PhD, is the Chief Executive Officer, Valitor, Inc. Dr. Jackson began working in biotechnology product development over 12 years ago as a part of a research partnership between the NIH and the Department of Defense. He co-founded Valitor as biotechnology company that has pioneered a unique and robust biophysics-based approach for engineering therapeutic proteins into next-generation drug products. Valitor's core technology was originally invented at UC Berkeley in the laboratories of his co-founders: Profs. Kevin Healy and David Schaffer. Dr. Jackson is now directing the R&D to commercialize this technology by developing drugs that will improve the treatment of diseases in many medical fields, including ophthalmology, inflammation, and immuno-oncology. Dr. Jackson received a B.S. from the Department of Bioengineering at UC Berkeley, and he received a Ph.D. from the Joint Graduate Program in Bioengineering at UCSF and UC Berkeley.

John Jacobsen, PhD, is Vice President of Chemistry at DiCE Molecules, a biotechnology company focused on the development of a unique approach to the identification of hits and leads for drug discovery by leveraging very large, DNA-encoded libraries of small molecules. Prior to joining DiCE, John was Senior Director of Medicinal Chemistry at Theravance Biopharma. At Theravance, John worked primarily in respiratory drug discovery and was a project leader for three inhaled therapeutic programs including two that entered clinical trials in partnership with GSK. John obtained his PhD from UC Berkeley with Peter Schultz on and went on to postdoctoral training with Chaitan Khosla at Stanford before joining the Medicinal Chemistry department at Theravance BioPharma (then known as Advanced Medicine, Inc.).

Angelika Jahreis, MD, PhD, completed her training at the Albert-Ludwig University of Freiburg, Germany. After her residency in dermatology, she conducted her postdoctoral fellowship at the Scripps Research Institute with Matthias von Herrath as a scholar of the German National Academy of Sciences. She has more than 15 years of global drug development experience across multiple indications, including rheumatology, dermatology, gastrointestinal diseases and pediatrics, and has been instrumental in the development of new therapeutics including etanercept, rituximab and tocilizumab at Amgen and most recently Genentech. She has been a FDA invited panel member and BIO representative to work with academia and regulators on pediatric registries. Recently her focus has been on developing medicines for patients with rare diseases.

Kurt Jarnagin, PhD, is an award-winning scientist capable of bridging science and business to achieve corporate and research objectives with a record of success managing transition from discovery to development and market phases. He has had successful IND, NDAs and market launches, a record of making key contributions, generating product and grant revenue. Additionally, he has demonstrated team leadership and organizational development to drive science breakthroughs and collaboration for exceptional performance in minimum resource environments and is a corporate spokesperson and scientific expert to global academic, scientific, regulatory, and business communities.

Chris Jones, MSE, has 25 years of experience in the medical device sector as an entrepreneur, executive, and inventor. Chris is currently consulting on several early stage medical device companies by providing product development, intellectual property, and business strategy guidance during pre-clinical and clinical phases of technology development. Previously, Chris was President and the first employee of AirXpanders and led the organization from inception through a successful international clinical trial of a smart, remotely controlled, patient-controlled, fully implantable tissue expander used in breast and burn reconstruction. Prior to AirXpanders, Chris was an Entrepreneur-in-Residence in a collaboration of several Silicon Valley medtech venture firms. Previously, Chris ran R&D departments for Magenta Medical and VNUS Medical Technologies and held earlier engineering management and product development positions at VidaMed and Stryker Endoscopy. Chris holds 43 U.S. patents related to medical technologies and products. Chris earned a B.S. degree in Mechanical Engineering from Stanford University and a M.S. degree in Engineering from the Massachusetts Institute of Technology.

Neena S. Kadaba, PhD, is an entrepreneur in residence at ATP, is a science-driven investor with 15 years of experience building novel collaborations and partnerships to drive innovation. Most recently, Neena was a Director at Quark Venture, where she served on the board of Eyevensys, IOME BIO, Calcimedica, and EyeYon on behalf of the Global Health Sciences Fund and led diligence for a number of additional investments. Previously, she was the Director of Strategic Partnerships at QB3, an institute at the University of California, where she created new programs to accelerate startups and worked with QB3's venture fund, Mission Bay Capital. Prior to QB3, Neena was a Kauffman Fellow while she was an Associate in Venture Investment at Itochu Technology, Inc, the California office of Itochu, the Japanese trading company, and she began her career in venture at California Technology Ventures.

Kevin Kabler, PhD, JD, is a partner in Goodwin's Technology Companies and Life Sciences group. He specializes in building and managing patent portfolios for life sciences companies and institutions. His practice involves strategic patent counseling and due diligence for clients at all stages of the business cycle, in addition to analysis and evaluation of third-party patents for mitigation of assertion risks and for investment purposes. He has extensive experience preparing and prosecuting domestic and international patent applications, and advising investors in assessing the competitive landscape, technology and intellectual property assets, and the risks associated with target investments. Prior to his legal career, he was a post-doctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.

Frank Kayser, PhD, is an expert in drug discovery, medicinal chemistry and structure-based drug design and has developed drug candidates for neuroscience, cardiovascular disease, metabolic disorders, oncology, and immunology. He led multidisciplinary teams that progressed compounds from early chemical leads into optimized clinical candidates, including multiple Ph2 and Ph1 clinical compounds. Frank held increasing research and management responsibilities in the pharmaceutical industry such as Merck, Tularik and Amgen, as a Director. Frank is an inventor on more than 40 US-issued and corresponding international patents and multiple pending US and PCT applications. He obtained his PhD in chemistry at the University of Marburg, Germany with Prof M. T. Reetz and was a postdoctoral fellow in the laboratories of Prof. B. H. Lipshutz at the University of California, Santa Barbara.

Shireen S. Khan, PhD, is currently a Director of Biologics at ChemPartner, located in South San Francisco, where she leads multiple therapeutic antibody discovery programs for small, mid-sized and large biotech and pharmaceutical companies. Prior to joining ChemPartner, Shireen led the in vitro cell and functional biology group at XOMA and advanced several therapeutic antibody candidates through proof of concept studies. Shireen has also held positions of increasing responsibility at biotech and medical diagnostic firms such as Chiron and Cholestech. She completed her PhD in Biology at the Salk Institute and Post-doctoral research at DNAX Research Institute in Palo Alto, CA where she studied cancer cell biology and cell cycle checkpoints that are activated in response to DNA damaging agents or spindle poisons.

David Kim, MD, MBA, has been involved in the entrepreneurial community in Silicon Valley since 2003 as venture capitalist. He has spent over a decade evaluating and working with companies in the healthcare sector initially at MPM Capital and then at Pinnacle Ventures as a Partner. David previously served as a general internist and hospitalist at Kaiser South San Francisco, where he also served as the Director of Urgent Care and Assistant Chief of Internal Medicine. David finished his internal medicine residency at Harbor-UCLA Medical Center and received his M.D. from the Johns Hopkins University School of Medicine. He is a graduate of Stanford Graduate School of Business (MBA) and Pomona College (BA in Biology).

Toni Kline, PhD, trained in organic medicinal chemistry and has professional experience in academia, big pharma and biotech. Toni has been designing and delivering small molecules for over 30 years. She used this background to address pathologies across a wide swath of biological as well as chemical space, with a primary focus on oncology and infectious disease. At Sutro Biopharma, she built a Chemistry group that would integrate the small molecule chemistry with the protein chemistry toward novel antibody-drug conjugates (ADCs). Toni was gratified to advance a natural product derivative through its stages of predevelopment and to progress it, conjugated to an antifolate antibody, to the clinic. In earlier work, at PathoGenesis/Chiron, Toni led the team pursuing target-based antibiotics, and identified the first LpxC inhibitor active against Pseudomonas aeruginosa. She is an advisor/consultant for biotech companies and academic groups, both in the Bay Area and on the East Coast; in this context, Toni manages several CROs both in the U.S. and abroad.Toni authored over 40 papers in peer-reviewed journals and hold inventorship on 10 patents.

June Lee, MD, serves as the COO at MyoKardia. Previously, June was the Director of Early Translational Research at Clinical and Translational Science Institute (CTSI) and a Professor in the School of Medicine at UCSF. A key focus of her work at UCSF was to identify the most compelling discovery research and enabling and supporting the projects towards product and commercialization. Prior to UCSF, she worked at Genentech as therapeutic area head and led early clinical development programs in Infectious Diseases, Cardiovascular/Metabolic Diseases, and Respiratory Diseases. She was responsible for the clinical strategy and execution of programs in the early clinical development stages and successfully developed pre-clinical and late stage research projects in a variety of therapeutic areas through IND clearance and early stage clinical proof of concept studies.

Michael D. Lesh, MD, FAAC, is a physician, scientist and entrepreneur. He earned undergraduate and graduate degrees in Computer Science and Bioengineering from the Massachusetts Institute of Technology (MIT) before entering medical school at the University of California San Francisco (UCSF). He is currently Co-founder and CEO at Syntegra. Dr. Lesh's career spans both sides of translational medicine. Dr. Lesh and his team pioneered numerous procedures for catheter ablation of cardiac arrhythmias. His research at UCSF led to the invention of a method for atrial fibrillation treatment known as pulmonary vein isolation. Atrionix, which he founded to commercialize this innovation, was acquired by Johnson and Johnson in 1999. Subsequently Dr. Lesh founded several successful start-up companies including Mitralife, Appriva, Evera Medical and Middle Peak Medical, where he served as CEO and President from conception to successful acquisitions.

Sarah Lively, PhD, is a skillful and dedicated Medicinal Chemist and Project Manager with extensive experience in the biopharmaceutical industry. Her expertise includes identification of lead small molecules with biological activity and optimization to FIH ready drug candidates. Additionally, Sarah has extensive alliance management, project leadership and team management experience. Prior to current work at Johnson & Johnson, Sarah was with ChemPartner, Nodality, Inc, Amgen, and Tularik. Sarah earned her PhD in synthetic organic chemistry from University of Sheffield, UK.

Sanjiv Luthra, MBA, is a digital health senior leader and advisor with 30+ years of operating and consulting experience. He is currently the EVP at Creda Health, a chronic condition management company for consumers. Sanjiv has held leadership positions at several healthcare companies including Medisafe (medication management), WebMD (health news and information), Conduent (health engagement), and Benu (employer health). In addition to his entrepreneurial experience, Sanjiv has been a consultant at several companies including Deloitte, Accenture, CSC, and Bain. His passion is creating, delivering, and managing health solutions for consumers that are personalized, relevant, connected, simple and affordable – whether they are patients, employees, members, retirees, or individuals.

Derek Maclean, PhD, is the senior chemical scientist with an unusually broad range of experience in pharmaceutical/biotech technology, research, and development. Dr. Maclean has extensive knowledge in the development of therapeutic peptide NCEs with 4 compounds advanced to clinic, and one to NDA/MAA (Parsabiv approved in US/EU/JP 2016/17) and significant experience in API / drug product manufacturing, process validation, CMC/Regulatory, outsourcing, supply-chain management, technology development for drug/biomarker discovery, and polymer therapeutic development.

Agatha Martindale, CPA, is a Senior Finance Executive with strong strategic experience in building pharmaceutical and medical device companies including equity financing, debt financing and IPOs. She is a CPA with experience working at Deloitte and private and public life science companies. She also worked at IdeaEdge Ventures, a high-tech start up incubator, funded by Qualcomm Ventures and has lead the Finance Team at multiple start-up companies. Agatha also has experience with M&A transactions and valuations.

William Mavity, is an experienced medical technology leader, who has served as the chief executive of: a subsidiary of a Fortune 50 company (3M Company); two publicly traded companies (NASDAQ: InnerDyne Medical and Cohesion Technologies) that were acquired by larger entities; and a half-dozen private companies, over a 28-year span. He has worked in the medical technology arena for more than 35 years.

Linda McAllister, MD, PhD, is currently a Technology Scout at Cepheid. Previously Dr. McAllister served as Chief Medical Officer at Revelar and VP of Scientific Affairs for Becton Dickinson. Prior to joining BD, Linda was CMO at Xagenic. Before joining Xagenic, Linda was CMO at a variety of diagnostic and device companies including PharmaJet, CellScape and ArborVita. Previously, Linda was Director of Technology Management at Roche Diagnostics where her work included technology assessment and strategic planning across the Roche business areas. Before joining Roche, Linda worked at Celera Dx and Affymetrix, where she helped develop the platforms and launch genetics-based products. Earlier in her career, Dr. McAllister was an Assistant Clinical Professor of Medicine at UCSF and an Attending Physician in the San Francisco General Hospital Emergency Room and UCSF Medicine Clinics. Linda holds an M.D. and Ph.D. from Stanford and a B.Sc. from the California Institute of Technology.

Jennifer Miller, PhD, is a life science entrepreneur with 20+ years of experience spanning public and private companies. Her current role is advising C-suite executives on business and strategy initiatives, where she leverages her deep experience in managing growth, from scaling R&D to navigating the R&D-to-commercial transformation. Jennifer previously held the positions of vice president of Corporate Development at Depomed and executive director of Corporate Development and Technology at Amphora Discovery. She began her career as a scientist where she held R&D leadership roles of increasing responsibility at Signature Bioscience, DuPont Pharma Research Labs and CombiChem. Jennifer has served as a "Big Data in Health" NIH SBIR grant program reviewer and as a member of MyoKardia's Digital Health Steering Committee. She earned her B.S. in Computer Science from San Diego State University and her PhD in Pharmaceutical Chemistry from UCSF.

Prasun Mishra, PhD, is an investor, co-founder and board member of a few US based corporations; has numerous publications/patents, several drugs in clinical trials, and has over 40 prestigious awards, honors to his credit. Dr. Mishra is also founding president and CEO of American Association for Precision Medicine (AAPM) and is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives.

Walter Moos, PhD, is a Managing Director of Pandect Bioventures, which he co-founded in 2018. Starting in 2016, first as an advisor, then as CEO, and now as Chairman emeritus of ShangPharma Innovation, he has led development of the group's innovation ecosystem. Moos has been an adjunct Professor of Pharmaceutical Chemistry at UCSF since 1992. He was President of SRI Biosciences until 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). Moos also managed corporate Information Technology Services at SRI. Earlier he was Chairman/CEO of MitoKor (Migenix) and a VP at Chiron (Novartis) and at Warner-Lambert/Parke-Davis (Pfizer). He and his teams have made significant contributions to all R&D phases from early-stage research on chemical and biological therapeutics and diagnostics to marketed pharmaceutical products. They have done this with the support of VCs, foundations, government agencies, big pharma, and many others. Moos has served on more than 20 business and scientific boards, public and private, non-profit and for-profit, including Alnis, Amunix, Anterion, Aprinoia, Axiom (Sequenom), the Biotechnology Industry Organization (BIO), Circle, the Critical Path Institute, Global Blood, Keystone Symposia, Migenix, Mimotopes (Fisher/Thermo), MitoKor, Oncologic (Aduro/Chinook), Onyx (Amgen), Rigel, ShangPharma Innovation, Valitor, and the Virginia University Research Partnership. He has advised companies on several continents and served as a committee member for academic, government, and investor groups, including the US National Academy of Sciences. He has co-founded several scientific journals, co-authored or edited multiple books, and has nearly 200 patents and publications. Moos has held faculty positions at several major universities and received PhD and AB degrees in chemistry from UC Berkeley and Harvard, respectively.

Swami Murugappan, MD, PhD, is an experienced hematologist oncologist with established track record in developing cell and gene therapies, oncolytics, monoclonal antibodies, and T cell engagers for solid and hematological cancers. He is currently the President and Owner of Trident Bio Consulting Inc which provides strategic and drug development support to biotech and pharmaceutical companies. Previously, he was Vice President at Nutcracker Therapeutics, a mRNA platform company, where he was responsible for non-clinical, regulatory, and clinical functions. He is a ABIM board-certified Hematologist and Oncologist. He completed his fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center after his Internal Medicine training at Drexel University. He graduated from Temple University with his PhD in Physiology and received his MD degree from Chennai Medical College, India.



Michael R. Myers, PhD, began his career in the pharma industry in 1987 as a medicinal chemist and has spent his career contributing to the discovery and development of new drugs. He has led drug discovery teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease. Mike has also led efforts in evaluating new lead generation technologies as well as improved processes in early drug discovery. Dr. Myers is an inventor on more than 35 patents. In 2001 Mike joined Eli Lilly & Co. from Aventis as a Research Fellow in Discovery Chemistry. From 2005 to 2008 he held the role of Sr. Director-Project Mgmt – Program Phase. From 2009 to present, Mike has been in the role of Sr. Director – LRL Due Diligence working with the External Innovation team of colleagues at Lilly. His team's main responsibilities are in leading Lilly's scientific & technical due diligence activities. Mike also has led elements of Lilly's Search & Evaluate team, supported academic outreach and has been an active partner with several of Lilly's strategic VC partnerships.

Mika Nishimura, MBA, is a senior executive with over 25 years of experience in successfully building businesses in the medtech markets. Throughout her medical device career, Mika has demonstrated deep operational expertise in launching new products and therapies, both in the US and internationally and across clinical segments. Mika currently serves as Vice President of Commercialization at nVision Medical and also as Operational Partner at Gilde Healthcare, trans-Atlantic venture fund focused exclusively on life sciences. Prior to these roles, Mika founded and built The BLG Group, a successful consulting practice advising both investors and device companies on critical strategic initiatives. Her previous positions include Vice President, Commercial Development at Auxogyn, Inc, Vice President of International Sales, Operations and Marketing at ev3 and Director of Global Marketing at Guidant Vascular, where she started and built franchises contributing significant, consistent revenue and profit growth with operations in over 30 markets. Mika holds an M.B.A. from Harvard Business School and a B.A. summa cum laude in Economics with distinction from Yale University.

Erica Pascal, PhD, JD, began her career in science studying the control of gene expression of mammals, plants and viruses. She received her B.S. degree in biology from the Massachusetts Institute of Technology. She obtained a Ph.D. in biochemistry and molecular biology from the University of California at Berkeley where she worked in the laboratory of Dr. Robert Tjian. Dr. Pascal did her post-doctoral work at the University of Illinois and then worked for 8 years in research and management in the biotech industry. She received her J.D. from California Western School of law., graduating summa cum laude. Prior to the creation of Ingensity™ IP, Dr. Pascal was a partner at a major global law firm. Her practice focused on strategic intellectual property issues for life sciences companies, including pharmaceuticals, biologics, diagnostic technologies and medical devices. Her experience includes strategic advice for life sciences companies, IP due diligence, litigation risk assessments, pre-trial and trial work. In addition to patent-related matters, Dr. Pascal has worked with clients on issues of false advertising and trade secret protection. Dr. Pascal is registered to practice as a patent attorney with the USPTO.

Rajan Patel, MS, is a medical device executive who partners with healthcare brands to transform their design & development practices. After 30+ years of medical device development across drug delivery, diagnostic systems, implantable devices and digital medicine, Rajan knows what truly drives innovation of smart, connected and patient-centric devices. It's about finding partners who are dedicated to creating breakthrough therapeutic solutions to unmet patient needs.

Anand Patel, MD, is the Chief of Interventional Radiology at Providence Little Company of Marys. He graduated from the University of Pennsylvania obtaining a degree in Bioengineering. He then completed his MD at Harvard Medical School, and an internal medicine internship at Beth Israel Deaconess. Dr. Patel completed his Radiology residency and Vascular & Interventional Fellowship at the University of California at San Francisco. His interests lie in interventional oncology (minimally invasive cancer treatments), women's health, interventional pain, peripheral arterial disease, venous disease, and MRI.
Dr. Patel aims to stay on the forefront of medical innovations, and is currently an Assistant Visiting Professor of Radiology at UCSF. He is a former CEO/Co-Founder of an NIH/National Cancer Institute funded med device startup for safer cost-effective liver cancer treatment.

Varun Paul, has worked across the Biotechnology and Healthcare sector, from Digital Health, Last Mile Rx Delivery, Pharmaceutical R&D, Clinical Operations, Production and Distribution to Integrated Healthcare Suppliers. He has spanned large firms and startups. He brings a strategic and operational excellence expertise, leading teams, achieving milestones & scaling solutions for stakeholders & patients.

Rick L. Pesano, MD, PhD, is the founder of Pesano Consulting, LLC and the former Vice President, Chief Medical Officer, Global Markets and Precision Medicine at Quest Diagnostics. His responsibilities at Quest included oversight of research and development activities for Quest's Infectious Disease Division and Companion Diagnostics. Dr. Pesano is a recognized leader in Infectious Diseases (including HIV and HCV) for both therapeutic and diagnostic fields. He works closely with the CDC and several state Public Health Departments in the areas of general infectious diseases, HIV and Hepatitis. Dr. Pesano was a member of the panel that developed CDC guidance documents for both HIV 4th Generation testing and HCV. Dr. Pesano received his B.A. in biochemistry from Canisius College in Buffalo, NY. He earned his PhD in Microbial Genetics from Worcester Polytechnic Institute in Worcester, MA and completed scientific training as a Howard Hughes research fellow. Dr. Pesano holds MD from Wake Forest University's Bowman Gray School of Medicine. He was trained in Internal Medicine and Adult Infectious Diseases and Geographic Medicine (international infectious diseases) at Stanford University.

Steve Pham, MD, is a practicing emergency medicine physician, a software engineer, and medical device expert. He previously launched a heart failure care delivery start-up bootstrapped off of Carbon Health, which demonstrated a 40% relative reduction in heart failure 30-day readmissions. He also led all clinical efforts at Eko Health, a digital stethoscope company, where he led on 6 hardware/software/AI-ML product life cycles, including 3 510ks, 1 breakthrough designation, $3.4M raised in SBIR funding, and an NHSx digital health pilot for heart failure. He now leads on medical device investments at Roivant.

Rupa Pike, PhD, MS, served as the Sr. Director of Technical Affairs for Advanced Therapies at Thermo Fisher Scientific. The Office of Technical Affairs comprises scientific experts that serve as a strategic, innovational and educational leaders in the area of cell-based therapies, plasmids and mRNA therapeutics. In her prior role as the Director of Enterprise Science and Innovation Partnerships, she developed and managed strategic partnerships with global BioPharma, Biotech and Healthcare customers in the area of Cell and Gene Therapy. Prior to this, she was the Head of Technical Operations (Patheon/Thermo Fisher Scientific) where she worked closely with customers to conduct technology transfer and process optimization activities related to GMP manufacturing of cell-based therapies. She has over 15 years of expertise in GMP manufacturing and has successfully led GMP operations, Process Development and MSAT activities, infrastructure buildout, customer relations and business development. In her past roles, she has been the Director of Cell Manufacturing for Program for Advanced Cell Therapy- UW Hospitals and Clinics.

David Pudwill, MSE, believes your decisions change the world and his mission at Mr. Regulatory is empowering people to make wise and informed decisions. David serves as Head of Regulatory Affairs at AscentX Medical and previously worked at ConvaTec, The U.S. Food and Drug Administration (FDA), and St. Jude Medical. He is a founding member of the Kidney Health Initiative, and has helped startups acquire funding and successfully interact with FDA. David holds a Master of Mechanical Engineering from Johns Hopkins University, a BSE in Biomedical Engineering from Case Western Reserve University, and a Certificate from HBX, now Harvard Business School Online.

Geetha Rao, PhD, MS, is an entrepreneur, executive, and strategic advisor to medical device, healthcare, and philanthropic organizations, addressing issues for high-risk technologies, including medical devices, health IT, and connected health systems. Particular focus on agile quality management and compliance strategy for rapid commercialization. Internationally recognized expert in risk management and serve on international standards and policy making bodies. Addressed numerous industry forums and the press on issues of emerging health technologies and innovation trends, especially for connected medical technologies.

Steven Richards, PhD, is a discovery scientist with over 15 years of medicinal chemistry expertise, hit-to-lead through candidate selection. This includes project leadership roles and experience working at both biotech and pharmaceutical companies. Adaptable approach to designing molecules to modulate kinases, NHRs, GPCRs, peptidases, glucosyltransferases, and dehydrogenases. Therapeutic area experience includes metabolic disease, cancer, and inflammation. Deliberate and thoughtful communication style facilitates collaborations. Able to develop drug discovery research strategies and direct multidisciplinary research efforts.

Jessica Richter joined Experien Group in 2017 to expand the firm's business development activities and to direct strategic growth initiatives. As COO, she works closely with the founders on thoughtful expansion and management responsibilities such as planning, hiring, business operations and performs due diligence for scalability that ensures the continued delivery of high-value services to all clients. She interfaces with U.S. and international executives, investors, legal representation and clinical and policy advisors to expand industry networks and to deliver meaningful support to the firm's clientele and partners. Jessica oversees Experien Group's operations, leads the business development team and coordinates with senior team members around client communications, deliverables definition, resource planning, budget estimates, project accounting, and results tracking to ensure client satisfaction. She delivers industry presentations representing Experien Group and informs the firm's collateral and training materials. Prior to Experien Group, Jessica spent six years in leadership roles within Medtronic, where she led sales and market development activities within the Early Technologies division. Previous to that experience, Jessica dedicated 10+ years to driving commercial sales activities within the medical device, software and communications arena. She concentrated on driving adoption of paradigm shifting platforms and remains passionate about patient-centric commercial advancement.

Andrew Rosenthal, joined Jawbone in 2013 through the acquisition of Massive Health, where he served as Chief Strategy Officer. Until mid-2016, he served as Group Manager for platform and wellness. He lead the company's focus on developer products, with a rich data platform serving over 3,500 community members, a "works with" partnership program, and major business development initiatives like partnerships with Nest and Huawei. While at Jawbone, he served as a company spokesperson, participated in fundraising pitches, worked with existing investors on strategic business development relationships, and had an FDA-regulated medical product in his portfolio. He has both industry and academic experience in behavior change interventions, with a long-term focus on using design and technology to help people live better. Andrew studied health policy and healthcare systems at the University of Pennsylvania and focused on healthcare and entrepreneurship at Harvard Business School. He has advised the Oliver Wyman Health Innovation Center and the Consumer Electronics Association (CEA) Health and Fitness Technology Board as well as a life sciences entrepreneurship course at UCSF.

Sharon Safrin, MD, FACP, is an independent consultant in biotechnology with over 15 years of experience. She has worked in all phases of drug development and has successfully authored and executed INDs, NDAs, MAAs, BLAs, SBIR grants, and peer-reviewed publications. Prior to incorporating as Safrin Clinical Research, she served as Director of Clinical Research at Gilead Sciences and as the project team leader for tenofovir and cidofovir. She spent 10 years on the full-time faculty at UCSF, based at SFGH in the Departments of Medicine and Epidemiology and Biostatistics. Her work at UCSF focused on clinical research in AIDS-related opportunistic infections, translational research in herpesviruses, and education in sexually transmitted diseases and methods of clinical research. She completed fellowships in Infectious Diseases, Clinical Epidemiology, and Clinical Pharmacology at UCSF following her medical internship and residency at Rhode Island Hospital.

Sam Saks, MD, is a board-certified oncologist who was most recently the founding CEO of Jazz Pharmaceuticals until his retirement in 2009. From 2001 until he joined Jazz, Saks was company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee. From 1992 until 2001, he held executive positions at ALZA, including group vice president, ALZA Pharmaceuticals, where he was responsible for clinical, regulatory and commercial activities. Prior to joining ALZA, Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Saks has a Bachelor's degree in biology and his medical degree from the University of Illinois. He completed his residency in internal medicine at Texas Southwestern, and his fellowship in oncology at the University of California – San Francisco, and is Board certified in both specialties. Saks is a director of Auspex Pharmaceuticals, TONIX Pharmaceuticals, Depomed, Bullet Biotechnology, NuMedii and Velocity Pharmaceutical Development**.**

Joshua Salafsky, PhD, is the CSO and Founder of Biodesy, LLC and the inventor of the SHG technique for detecting conformational change in biomolecules. Prior to founding Biodesy, he was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, and a guest researcher at the Cavendish Laboratory at the University of Cambridge. During this time, he invented 'SHG labels' and the first single-nanocrystal photovoltaic device, a new and highly efficient architecture for photoelectric and solar-cell devices. A nanotechnology company is commercializing the device, while academic groups at Stanford, Berkeley and the University of Tokyo are studying its design and pursuing its full potential. Dr. Salafsky's expertise and interests are in the areas of Biophysics and Physical Chemistry. With Biodesy, he and his colleagues are developing SHG into a tool for drug discovery and real time and space measurements of conformational change. The applications developed at Biodesy all have conformational change as their common theme. Dr. Salafsky received his PhD from Stanford University where he studied the reaction center protein, the engine at the heart of photosynthesis that converts light into chemical energy.

David Savello, PhD, is Venture Advisor & Scientific Advisory Board Member at Pappas Ventures. He regularly provides clinical development guidance to the portfolio companies – including CoLucid Pharmaceuticals, Milestone Pharmaceuticals and Lumena Pharmaceuticals, for which he was a member of the board of directors prior to its acquisition by Shire in 2014. Dave was most recently Senior Vice President of Development Operations for Xenoport. Prior to Xenoport, he co-founded NDA Partners, a drug development consulting company.

Mark Scheideler, PhD, founded HumanFirst Therapeutics LLC (HFT) in 2011 with the goal of accelerating new therapies towards clinical development, by providing the expertise needed to form, fund and operationally manage life science projects. HFT provides Managing Partner expertise to public-private alliances aimed at drug development, to include: research direction; path-to-clinic planning; medicinal chemistry; project and consortium management; agreement support and patenting; and public funding. Clients have included Universities and Disease Foundations seeking to progress therapeutic opportunities, and Companies pursuing drug development via public sector collaboration.

Howard Schulman, PhD, is CEO and CSO of Allosteros Therapeutics, Inc. a company he co-founded to develop kinase-based therapeutic drugs for cardiovascular indications. He has received VC support as well as multiple SBIR grants to develop selective and potent small molecule inhibitors of CaMKII, with preclinical proof of concepts in atrial fibrillation and ventricular arrhythmia. Dr. Schulman received his B.S. in chemistry from UCLA and his Ph.D. in biological chemistry at Harvard University, studying phospholipid metabolism with Eugene P. Kennedy. Subsequently he undertook postdoctoral research in signal transduction in the Department of Pharmacology at Yale under the supervision of Nobel Laureate Paul Greengard. He was a faculty at Stanford University for 20 years, in the Departments of Pharmacology and of Neurobiology. He was most recently the Chair of the Department of Neurobiology and co-founder and co-director of the Stanford Brain Research Center. Dr. Schulman spent the past 15 years in industry focusing on therapeutic targeting of protein kinases based on structural and mechanistic insights and use

of biomarkers in drug development. He joined SurroMed as Vice President, a biomarker discovery company whose biomarker assets were acquired by PPD, where he was Vice President of PPD Biomarker Discovery Sciences. As a scientist, he has been a major contributor to progress in the field of molecular pharmacology and signal transduction research for more than 25 years. Dr. Schulman co-discovered CaMKII, one of the key protein kinases responsible for transmitting information from calcium-linked hormones, cytokines and neurotransmitters in diverse tissues. He is a Fellow of the American Association for the Advancement of Science.

Christopher Seaman, PhD, has led growth and data science teams at two unicorns, aiding in successful IPO exits. His work includes all stages of the customer life cycle and product development. Prior to joining tech he worked as a researcher in health outcomes and biotech, including pharmaceutical, diagnostic, and genomic research.

Julia Seaman, PhD, has extensive experience in survey research as well as competitive intelligence and translational research. She has worked and published across a wide range of qualitative and quantitative projects. Along with her publications at Bay View Analytics, Dr. Seaman's projects include publishing on statistical practices in ASQ, and consulting for several biotechnology start-ups. Dr. Seaman has published in scientific, statistical, and quality control journals, including Cell Death and Differentiation, BMC Anesthesiology, and Journal of Quality Progress, as well as serving as statistical and scientific reviewer for BMC journals and UCSF Health Awards. Dr. Seaman earned her doctorate in Pharmaceutical Chemistry and Pharmacogenomics from the University of California, San Francisco (UCSF). Her research focused on improving healthcare outcomes through optimized treatments utilizing new technologies and analytical techniques. After completing her PhD, she moved into healthcare consulting, working with leading biotechnology companies as a strategy and competitive intelligence partner.

Biren Shah, MBA, is an accomplished biotechnology innovator that has lead a variety of functions and product launches throughout his career. His diverse experience in global drug development, partnering and commercialization provides a comprehensive perspective in competitive therapeutic areas. Biren's focus on differentiated strategies and creative tactics has delivered stakeholder value for many life science companies.

Martin Shapiro, MD, MBA, is a UCSF Family and Community Medicine Resident passionate about driving forward healthcare innovation with health technology. Hailing from Los Angeles, California, Dr. Shapiro attended Yale studying mechanical engineering with a focus on medical device design. Continuing his study of health innovation, he completed his MD/MBA with a graduate certificate in Health, Technology, and Engineering at USC. During medical school, he supported efforts to integrate technology into global health care delivery in Cambodia and Guatemala. As a Senior Venture Architect for Boston Consulting Group Digital Ventures, he built healthcare startups and drove thought leadership in clinical artificial intelligence and digital therapeutics. In addition, Dr. Shapiro served as the Primary Care Innovation Fellow at the American Academy of Family Physicians researching the intersection of technology and primary care. Outside of residency, Dr. Shapiro enjoys playing volleyball, exploring the outdoors, and traveling.

Rupa Shetty, PhD, serves as Principal Scientist Medicinal Chemistry at Olema Oncology. At Olema she is involved in design and synthesis of novel Estrogen Receptor antagonists as therapy for ER+ breast cancer. Prior to Olema, she was at Prelude Therapeutics in the Medicinal Chemistry department. At Prelude she contributed to four oncology targets which resulted in identification of compounds that are currently in Phase I or IND studies. Rupa has extensive experience in Structure Based Drug Design, Optimization of small molecules for preclinical studies, also have experience with design of Protein Degraders and Antibody drug conjugates.

Sunil Singh, PhD, is of-counsel with the firm Young Basile's Palo Alto office and concentrates his practice in all facets of patent prosecution and counseling in the fields of biotechnology, pharmaceuticals, drug delivery, medical devices, organic chemistry and materials science. Dr. Singh has extensive research experience in the pharmaceutical arts and has practiced patent law for over 15 years, primarily in the life sciences. He has prepared and prosecuted numerous patent applications, written invalidity, infringement and clearance opinions and has advised clients on patents issues related to corporate transactions and other strategic problems such as portfolio design and pharmaceutical exclusivity.

John Sninsky, PhD, has been Chief Scientific Officer of CareDx, Inc since January 05, 2014 Dr. Sninsky has a wealth of experience in the discovery, development and application of diagnostic technologies, content and interpretive test solutions. Dr. Sninsky has significant experience ranging from early stage biotechnology to international pharmaceutical organizations as well as a range of CLIA and IVD product settings. He was instrumental in recognizing the importance and bringing pioneering companion diagnostics to the treatment of HIV. In addition, following determination of the sequence of first human genome at Celera Genomics, Dr. Sninsky oversaw a sequencing study to uncover human genetic variation, a prerequisite to his team embarking on early and extensive functional genetic association studies. He served as the Vice President of Discovery Research at Celera Corporation. He served as the Alameda site head for Quest's Science & Innovation and oversaw organization-wide Bioinformatics.

David Spellmeyer, PhD, is a biotechnology executive with 25 years of broad experience in the life sciences industry. He currently serves as CSO at Circle Pharma, an SPII VC portfolio company and heads Interlaken Associates where he advises early-stage companies and investors on corporate and technical strategy, product development, commercialization, and funding. He previously served as CTO & CIO at Nodality and in research leadership roles at both large and small companies. Dr. Spellmeyer received his BS in computer science and chemistry from Purdue University and his PhD in theoretical organic chemistry from UCLA. He completed postdoctoral training in pharmaceutical chemistry at UCSF, where he is an adjunct Associate Professor.

Gary Starling, PhD, has focused his career on the discovery and early development of biologic therapeutics. He held key positions at Bristol-Myers Squibb, CuraGen, PDL BioPharma, Facet Biotech (acquired by Abbott Labs) and Merck. He led the Protein Science Department at Merck that drove the discovery of Biologics for all of Merck's disease areas including Immuno-Oncology. Now, Gary serves as President and Chief Scientific Officer of Astella Pharma and creates novel cell therapies to fight cancer.

David Steuer is currently Executive Director, Healthcare Practice Lead at frog design, a leading global design and strategy firm. David is dedicated to applying human-centered design to create more effective, humane, and affordable healthcare for everyone. He works with business strategists, designers and engineers to identify hidden opportunities, tackle complex systemic challenges, and help both major players and entrepreneurial start-ups to bring new products and services to market that make the promise of better health real. Previously, David was a founder of Saatchi & Saatchi. Before Saatchi, he was with Sawyer Media, Scient, and ATG.

Pilar Stillwater, JD, is a counsel in the Intellectual Property and Litigation groups in Crowell & Moring's San Francisco office, with a background in molecular and cell biology. Her practice focuses on intellectual property litigation, with an emphasis on patent infringement disputes. Pilar has litigated patent infringement cases involving a wide range of technologies, including pharmaceuticals, prefabricated concrete slabs, and wireless LAN technology. Pilar also counsels clients on patent infringement and licensing issues in the medical device and biopharmaceutical areas. Pilar earned her B.S. in molecular, cell, and developmental biology with highest honors in the major and college honors from the University of California, Santa Cruz in 2004. She received her J.D. from the University of California, Hastings, cum laude, in 2008, where she was the executive production editor of the Hastings Law Journal. Prior to joining Crowell in 2012, Pilar was an associate in a prominent San Francisco litigation boutique firm, where she represented both plaintiffs and defendants in patent infringement and complex commercial litigation disputes. Pilar is actively involved in pro bono work and has represented clients in debt-collection and copyright disputes.



Jessica Sun, MD, PhD, is Sr. Director, Head of In Vivo Pharmacology at Terremoto Biosciences. She has over 17 years of industrial experience focusing on drug discovery and development in the field of cancer, inflammatory, metabolic, renal, and liver disease. Jessica utilizes translational and biomarker sciences in preclinical models to facilitate fast development of pipeline molecules and has a proven track of transitioning small molecules from preclinical to early clinical development. Jessica started her healthcare career as a physician in China; after moving to the US, she entered industry at Y's Therapeutics and went on to work for several biotech companies such as Threshold Pharmaceuticals, Reset Therapeutics, and ORIC Pharmaceuticals. Jessica received her MD from China Medical University, a PhD in Medical Sciences from Hamamatsu University School of Medicine and completed a postdoctoral training at Stanford University School of Medicine.

Jordan Sun, MBA, is a Director of Venture Development at Siemens Healthineers Digital Incubator. Jordan brings healthcare, venture capital, and public service experiences. He previously served as the interim Head of Business Development for Zap Surgical Systems, a Foxconn-backed robotic radiosurgery startup, and as an Investments Consultant with In-Q-Tel, the US Intelligence Community's strategic venture fund. Jordan is currently a Captain/Technology Scout for the US Army Reserve Innovation Command to drive the Army's modernization partnerships with startups in AI, healthcare, robotics, and other critical technologies. He also served as a US Diplomat with the US Department of State focused on the intersection of tech and national security. Jordan attended New York University for his undergraduate studies and Yale University for graduate school.

Connie Tat, PhD, has over 8 years of diverse experiences in the biotech/pharma industry in the US and globally in roles in Medical Affairs, Clinical Development, Competitive Intelligence, consulting and equity research. She is currently a Senior Medical Science Director in Oncology in Medical Affairs at Genentech, where she partners closely with Commercial to develop an integrated launch and portfolio strategy for registrational clinical trials. In this role, she evaluates proposals, assesses the strategic, scientific and clinical fit and works closely with investigators from academia and industry partners to drive these studies through key milestones. Previously, she launched LUMAKRAS (sotorasib; a first in class KRAS G12C inhibitor) in metastatic non-small cell lung cancer in Canada, Brazil, and UAE at Amgen. There, she also served as the Intercontinental Regional Medical Lead and developed the medical strategy for the oncology pipeline portfolio across solid tumors and hematology with assets of various modalities and in different stages of development. She earned her Ph.D. in Immunology from the University of California, Irvine and her Bachelor's in Molecular and Cellular Biology from the University of California, Berkeley. She is passionate about translating innovative research and technology to improve patient outcomes.

Ian Tong, MD, is Chief Medical Officer of Doctor On Demand. He is also Clinical Assistant Professor (Adjunct) at Stanford University Medical School and has staff privileges at the VA Palo Alto Health Care System. Prior to joining Doctor On Demand, Dr. Tong had multiple medical leadership roles including former Stanford Internal Medicine Chief Resident, Founder and Medical Director of THRIVE (The Health Resource Initiative for Veterans Everywhere), which was honored in 2008 with the VA Secretary's Award for Outstanding Achievement in Service to Homeless Veterans and Co-Medical Director of the Arbor Free Clinic. Dr. Tong earned a medical degree from The University of Chicago-Pritzker. He is board certified in Internal Medicine. He completed residency and Chief residency at Stanford Hospital and Clinics. Ian was a three-time National Collegiate Champion in Rugby at the University of California at Berkeley and was named to the All-American Team in 1994. He lives in Walnut Creek with his wife and three children.

Peter Virsik, MBA, MS, joined ESSA in August 2016 as Executive Vice President and Chief Operating Officer, bringing over 20 years experience in corporate development, strategy, new product planning, alliance management, and finance. During his career, Mr. Virsik has completed over 30 licensing, M&A and financial transactions, totaling over $3 billion in value. Most recently, he served as Senior Vice President, Corporate Development for XenoPort (acquired by Arbor Pharmaceuticals), leading licensing, strategy, new product planning and alliance management for the company. During his tenure at XenoPort, Mr. Virsik played an integral role in the licensing and commercialization of Horizant® (gabapentin enacarbil). Prior to XenoPort, Mr. Virsik worked for Gilead Sciences from 2000 through 2005 in Corporate Development, where he was involved in building Gilead's HIV franchise through the acquisition of Triangle Pharmaceuticals and the licensing of Vitekta® (elvitegravir). Before joining Gilead, Mr. Virsik worked at J.P. Morgan in the biotechnology equity research group and as a consultant for Ernst and Young. Mr. Virsik began his career in R&D at Genentech. Mr. Virsik received an MBA from the Kellogg Graduate School of Management at Northwestern University, an MS in Microbiology from the University of Michigan, Ann Arbor, and a BA in Molecular and Cellular Biology from the University of California, Berkeley.

Colin Walsh, PhD, is a Principal at Qiming Venture Partners USA, based in Los Altos, CA. Before joining Qiming in April 2019, Dr. Walsh was a Vice President on the life science investment team at NanoDimension where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to NanoDimension, Dr. Walsh was an early employee at Precision NanoSystems (PNI), a 5AM Ventures backed biotech startup developing a suite of technologies to enable the development and manufacture of complex drug formulations. At PNI, he focused extensively on RNA- and DNA- based therapeutics, and held a variety of product and business development roles where he worked closely with management to define the strategy and direction of the business.



Rong Wang is passionate about the life science and technology industries, motivated by the noble causes and the challenges from high levels of complexities. Having advised multiple start-up companies towards funding, as well as served in high growth medical device, diagnostic, robotics, and digital service firms, Rong looks forward to leading and scaling a company to its next level of success.

Daniel Weberg, PhD, MHI, RN, is an expert in nursing, healthcare innovation and human-centered patient design with extensive clinical experience in emergency departments, acute in-patient hospital settings and academia. He currently serves as the Head of Clinical Innovation for Trusted Health, the staffing platform for the healthcare industry, where he helps drive product strategy and works to change the conversation around innovation in the healthcare workforce.

Cameron Wheeler, PhD, is a Principal on the Private Transactions team at Deerfield. Cameron joined Deerfield in 2014 and focuses on therapeutics companies. Prior to joining Deerfield, Cameron was at Eleven Biotherapeutics for more than five years, where he was responsible for corporate development and commercial strategy. He was instrumental in the founding, building, and the eventual public offering of Eleven Biotherapeutics. Prior to Eleven, Cameron was at Third Rock Ventures, a Boston-based venture capital firm focused on launching and building life science companies. While at Third Rock, Cameron gained

business development and operating experience as a member of the founding team of Constellation Pharmaceuticals. Cameron holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from Massachusetts Institute of Technology.

Sue Wollowitz, PhD, (president at Wollowitz Associates LLC) is a pharmaceutical development consultant and educator. She has worked in process and product development supporting oral, parenteral and topical products as well as clinical materials management and drug/device combinations for a variety of indications. She has worked with many small pharma companies including partnered, in-licensed and out-licensed projects with many large pharma companies. She teaches at UC Berkeley Extension as part of their semi-annual seminar on the Drug Development Process. Prior to returning to consulting in 2014, Sue was VP of Pharmaceutical Operations at Medivation, Inc. Previously Sue has held positions at Cerus Corporation and Dow Chemical Company. She is the holder of 32 patents and the author of over 20 publications. Wollowitz has a PhD in organic chemistry from the University of Wisconsin at Madison and further trained at CNRS in France and at the University of Chicago.

Sam Wu, MD, PhD, is the Managing Director at Acuris Partner. Previously, Dr. Wu served as Managing Director at MedImmune Ventures and led their West Coast office. Dr. Wu is or has been a board member of Applied Genetic Technologies Corp (NASDAQ:AGTC), Cerapedics, and VaxInnate. Previously he was a principal with SV Life Sciences, a healthcare-focused venture capital firm he had joined in 2002, where he invested in a broad range of biopharmaceutical, platform and medical device companies. Before moving into venture capital, he was an Engagement Manager in the Pharmaceuticals and Corporate Finance practices of McKinsey and Company, where he led teams of consultants serving clients on M&A, portfolio analysis and other strategic issues. Sam holds an A.B. magna cum laude in Biochemistry from Harvard College, attended Stanford University School of Medicine where he earned an M.D. and a Ph.D. in Biochemistry as a Howard Hughes Predoctoral Fellow, and trained in Internal Medicine at the University of California, Los Angeles.

Wentao Zhang, PhD, MS, is Founder and President at Quintara Discovery, where he utilizes his extensive expertise in drug discovery and lead profiling to provide the best services in the area of ADME, PK bioanalysis and assay development. Quintara Discovery (QDI) offers an extensive suite of assays including P450 inhibition and induction, permeability, solubility, metabolic stability, interactions with drug transporters, GLP and non-GLP bioanalysis and label-free detection services.